Final cumulative pooled IBD safety data support the longstanding safety profile of STELARA across all IBD approved indications Additional long term extension data demonstrate more than half of STELARA ...

55.2 percent of induction responder patients treated with STELARAat the start of maintenance were in symptomatic remission approximately four years later (at week 200), 96.4 percent without ...

Johnson & JohnsonJNJ announced new data from a phase III study, evaluating its drug Stelara in adults with moderate-to-severe ulcerative colitis ("UC"). The eight-week induction data from the pivotal ...

Johnson & Johnson's Janssen unit said on Friday it would discontinue a late-stage study testing its psoriatic arthritis drug Stelara as a treatment for lupus as it was not found to be effective ...

Johnson & Johnson raised its 2023 profit forecast in its first earnings report since spinning off its consumer health business, with the company's fortunes now tied more closely to sales of ...